Cipla (LUX:CIPLA) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 12, 2026)


LUX:CIPLA Cipla Ltd LUX:CIPLA
95 GF Score
Price $18.10
GF Value $19.80
! 5 Warning Signs
View Full Analysis

What is Cipla 5-Year Yield-on-Cost %?

Cipla LUX:CIPLA 95 5-Year Yield-on-Cost % is 0.00 as of Jul. 12, 2026. GuruFocus rates LUX:CIPLA with a GF Score™ of 95/100 and a GF Value™ of $19.80. The stock has 5 warning signs investors should review. Among 516 Drug Manufacturers companies, Cipla ranks worse than 73.26% on this metric.

Cipla's yield on cost for the quarter that ended in Mar. 2026 was 0.00.


The historical rank and industry rank for Cipla's 5-Year Yield-on-Cost % or its related term are showing as below:


During the past 13 years, Cipla's highest Yield on Cost was 1.75. The lowest was 0.30. And the median was 0.54.


LUX:CIPLA's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.205
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Cipla  (LUX:CIPLA) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Cipla 5-Year Yield-on-Cost % Related Terms


LUX:CIPLA vs ZTS, UTHR: 5-Year Yield-on-Cost % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cipla's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cipla 5-Year Yield-on-Cost % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cipla's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Cipla's 5-Year Yield-on-Cost % falls into.


LUX:CIPLA
95GF Score
Cipla Ltd LUX:CIPLA
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cipla 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Cipla is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Cipla (LUX:CIPLA) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 12, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Cipla and its competitors. Over the past decade, Cipla's 5-Year Yield-on-Cost % has ranged from 0.30 to 1.75. According to the industry distribution chart, Cipla ranks #378 out of 516 companies in the Drug Manufacturers industry, placing it in the top 73.3%.
Is Cipla's 5-Year Yield-on-Cost % too high?
Cipla's current 5-Year Yield-on-Cost % is 0.00. Over the past 10 years, this metric has ranged from a low of 0.30 to a high of 1.75. Based on the distribution chart, Cipla ranks #378 out of 516 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Cipla has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does Cipla's 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cipla ranks #378 out of 516 companies for 5-Year Yield-on-Cost %. This places Cipla in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.21. Historically, Cipla's own 5-Year Yield-on-Cost % has ranged from 0.30 to 1.75 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.21, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Cipla and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cipla's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cipla stock overvalued right now?
Cipla (LUX:CIPLA) has a current 5-Year Yield-on-Cost % of 0.00. The stock's GF Value™ is $19.80, compared to a current price of $18.10 — trading 8.6% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Cipla's overall GF Score™ is 95/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Cipla (LUX:CIPLA), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cipla (LUX:CIPLA) Overvalued in 2026?

Based on GuruFocus' analysis, Cipla stock appears to be undervalued. The current stock price of $18.10 is trading 8.6% below its estimated GF Value™ of $19.80.

Key valuation signals for LUX:CIPLA:

  • 5-Year Yield-on-Cost %: 0.00
  • GF Value™: $19.80 vs. price of $18.10 (8.6% below fair value)
  • GF Score™: 95/100 with 5 warning signs

No single metric tells the full story. See the LUX:CIPLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cipla Business Description

Other Exchanges CIPLA:India500087:India
Address Ganpatrao Kadam Marg, Cipla House, Peninsula Business Park, Lower Parel, Mumbai, MH, IND, 400 013
Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. The bulk of its sales are generated in India, although it maintains a large world-wide presence. Cipla's growth plan focuses on new product launches. It has two segments Pharmaceuticals and new ventures. It derives maximum revenue from Pharmaceuticals Segment.
95GF Score

Get the complete analysis for LUX:CIPLA

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.10
Price
$19.80
GF Value